Tenecteplase versus alteplase for the treatment of acute ischemic stroke: a meta-analysis of randomized controlled trials

References

• Ospel JM, Holodinsky JK, Goyal M. Management of acute ischemic stroke due to large-vessel occlusion: JACC focus seminar. J Am Coll Cardiol. 2020;75(15):1–12. doi: 10.1016/j.jacc.2019.10.034.
   Web of Science ®Google Scholar
• Coutts SB, Berge E, Campbell BC, et al. Tenecteplase for the treatment of acute ischemic stroke: a review of completed and ongoing randomized controlled trials. Int J Stroke. 2018;13(9):885–892. doi: 10.1177/1747493018790024.
   PubMed Web of Science ®Google Scholar
• Burgos AM, Saver JL. Evidence that tenecteplase is noninferior to alteplase for acute ischemic stroke: meta-analysis of 5 randomized trials. Stroke. 2019;50(8):2156–2162. doi: 10.1161/STROKEAHA.119.025080.
   PubMed Web of Science ®Google Scholar
• Kheiri B, Osman M, Abdalla A, et al. Tenecteplase versus alteplase for management of acute ischemic stroke: a pairwise and network meta-analysis of randomized clinical trials. J Thromb Thrombolysis. 2018;46(4):440–450. doi: 10.1007/s11239-018-1721-3.
   PubMed Web of Science ®Google Scholar
• Keyt BA, Paoni NF, Refino CJ, et al. A faster-acting and more potent form of tissue plasminogen activator. Proc Natl Acad Sci U S A. 1994;91(9):3670–3674. doi: 10.1073/pnas.91.9.3670.
   PubMed Web of Science ®Google Scholar
• Benedict CR, Refino CJ, Keyt BA, et al. New variant of human tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human TPA. Circulation. 1995;92(10):3032–3040. doi: 10.1161/01.cir.92.10.3032.
   PubMed Web of Science ®Google Scholar
• Nepal G, Kharel G, Ahamad ST, et al. Tenecteplase versus alteplase for the management of acute ischemic stroke in a low-income country-Nepal: cost, efficacy, and safety. Cureus. 2018;10(2):e2178. doi: 10.7759/cureus.2178.
   Google Scholar
• Tanswell P, Modi N, Combs D, et al. Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction. Clin Pharmacokinet. 2002;41(15):1229–1245. doi: 10.2165/00003088-200241150-00001.
   PubMed Web of Science ®Google Scholar
• Gao L, Moodie M, Mitchell PJ, et al. Cost-effectiveness of tenecteplase before thrombectomy for ischemic stroke. Stroke. 2020;51(12):3681–3689. doi: 10.1161/STROKEAHA.120.029666.
   PubMed Web of Science ®Google Scholar
• Coutts SB, Dubuc V, Mandzia J, et al. Tenecteplase-tissue-type plasminogen activator evaluation for minor ischemic stroke with proven occlusion. Stroke. 2015;46(3):769–774. doi: 10.1161/STROKEAHA.114.008504.
   PubMed Web of Science ®Google Scholar
• Campbell BCV, Mitchell PJ, Churilov L, et al. Effect of intravenous tenecteplase dose on cerebral reperfusion before thrombectomy in patients with large vessel occlusion ischemic stroke: the EXTEND-IA TNK part 2 randomized clinical trial. JAMA. 2020;323(13):1257–1265. doi: 10.1001/jama.2020.1511.
   PubMed Web of Science ®Google Scholar
• Bivard A, Zhao H, Churilov L, et al. Comparison of tenecteplase with alteplase for the early treatment of ischaemic stroke in the Melbourne Mobile Stroke Unit (TASTE-A): a phase 2, randomised, open-label trial. Lancet Neurol. 2022;21(6):520–527. doi: 10.1016/S1474-4422(22)00171-5.
   PubMed Web of Science ®Google Scholar
• Kvistad CE, Næss H, Helleberg BH, et al. Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial. Lancet Neurol. 2022;21(6):511–519. doi: 10.1016/S1474-4422(22)00124-7.
   PubMed Web of Science ®Google Scholar
• Li S, Pan Y, Wang Z, et al. Safety and efficacy of tenecteplase versus alteplase in patients with acute ischaemic stroke (TRACE): a multicentre, randomised, open label, blinded-endpoint (PROBE) controlled phase II study. Stroke Vasc Neurol. 2022;7(1):47–53. doi: 10.1136/svn-2021-000978.
   PubMedGoogle Scholar
• Menon BK, Buck BH, Singh N, et al. Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial. Lancet. 2022;400(10347):161–169. doi: 10.1016/S0140-6736(22)01054-6.
   PubMed Web of Science ®Google Scholar
• Wang Y, Li S, Pan Y, et al. Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferiority trial. Lancet. 2023;401(10377):645–654. doi: 10.1016/S0140-6736(22)02600-9.
   PubMed Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi: 10.1136/bmj.n71.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343(2):d5928. doi: 10.1136/bmj.d5928.
   PubMed Web of Science ®Google Scholar
• Lin CH, Saver JL, Ovbiagele B, et al. Endovascular thrombectomy without versus with intravenous thrombolysis in acute ischemic stroke: a non-inferiority meta-analysis of randomized clinical trials. J Neurointerv Surg. 2022;14(3):227–232. doi: 10.1136/neurintsurg-2021-017667.
   Web of Science ®Google Scholar
• Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–560. doi: 10.1136/bmj.327.7414.557.
   PubMed Web of Science ®Google Scholar
• Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–634. doi: 10.1136/bmj.315.7109.629.
   PubMed Web of Science ®Google Scholar
• Haley ECJr., Thompson JL, Grotta JC, et al. Phase IIB/III trial of tenecteplase in acute ischemic stroke: results of a prematurely terminated randomized clinical trial. Stroke. 2010;41(4):707–711. doi: 10.1161/STROKEAHA.109.572040.
   PubMed Web of Science ®Google Scholar
• Campbell BCV, Mitchell PJ, Churilov L, et al. Tenecteplase versus alteplase before thrombectomy for ischemic stroke. N Engl J Med. 2018;378(17):1573–1582. doi: 10.1056/NEJMoa1716405.
   PubMed Web of Science ®Google Scholar
• Huang X, Cheripelli BK, Lloyd SM, et al. Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study. Lancet Neurol. 2015;14(4):368–376. doi: 10.1016/S1474-4422(15)70017-7.
   PubMed Web of Science ®Google Scholar
• Logallo N, Novotny V, Assmus J, et al. Tenecteplase versus alteplase for management of acute ischaemic stroke (nor-TEST): a phase 3, randomised, open-label, blinded endpoint trial. Lancet Neurol. 2017;16(10):781–788. doi: 10.1016/S1474-4422(17)30253-3.
   PubMed Web of Science ®Google Scholar
• Parsons M, Spratt N, Bivard A, et al. A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. N Engl J Med. 2012;366(12):1099–1107. doi: 10.1056/NEJMoa1109842.
   PubMed Web of Science ®Google Scholar
• Katsanos AH, Psychogios K, Turc G, et al. Off-label use of tenecteplase for the treatment of acute ischemic stroke: a systematic review and meta-analysis. JAMA Netw Open. 2022;5(3):e224506. doi: 10.1001/jamanetworkopen.2022.4506.
   PubMed Web of Science ®Google Scholar
• Ma P, Zhang Y, Chang L, et al. Tenecteplase vs. alteplase for the treatment of patients with acute ischemic stroke: a systematic review and meta-analysis. J Neurol. 2022;269(10):5262–5271. doi: 10.1007/s00415-022-11242-4.
   PubMed Web of Science ®Google Scholar
• Oliveira M, Fidalgo M, Fontão L, et al. Tenecteplase for thrombolysis in stroke patients: systematic review with meta-analysis. Am J Emerg Med. 2021;42:31–37. doi: 10.1016/j.ajem.2020.12.026.
   PubMed Web of Science ®Google Scholar
• Katsanos AH, Safouris A, Sarraj A, et al. Intravenous thrombolysis with tenecteplase in patients with large vessel occlusions: systematic review and meta-analysis. Stroke. 2021;52(1):308–312. doi: 10.1161/STROKEAHA.120.030220.
   PubMed Web of Science ®Google Scholar
• Thelengana A, Radhakrishnan DM, Prasad M, et al. Tenecteplase versus alteplase in acute ischemic stroke: systematic review and meta-analysis. Acta Neurol Belg. 2019;119(3):359–367. doi: 10.1007/s13760-018-0933-9.
   PubMed Web of Science ®Google Scholar
• Kobeissi H, Ghozy S, Turfe B, et al. Tenecteplase vs. alteplase for treatment of acute ischemic stroke: a systematic review and meta-analysis of randomized trials. Front Neurol. 2023;14:1102463. doi: 10.3389/fneur.2023.1102463.
   Web of Science ®Google Scholar
• Berge E, Whiteley W, Audebert H, et al. European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke. Eur Stroke J. 2021;6(1):I–LXII. doi: 10.1177/2396987321989865.
   PubMed Web of Science ®Google Scholar
• Nair R, Wagner AN, Buck BH. Advances in the management of acute ischemic stroke. Curr Opin Neurol. 2023;36(2):147–154. doi: 10.1097/WCO.0000000000001136.
   Web of Science ®Google Scholar
• Huang X, MacIsaac R, Thompson JL, et al. Tenecteplase versus alteplase in stroke thrombolysis: an individual patient data meta-analysis of randomized controlled trials. Int J Stroke. 2016;11(5):534–543. doi: 10.1177/1747493016641112.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Xu X, Ni H. Small studies may overestimate the effect sizes in critical care meta-analyses: a meta-epidemiological study. Crit Care. 2013;17(1):R2. doi: 10.1186/cc11919.
   PubMed Web of Science ®Google Scholar